FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis - Concepedia

Concepedia

Publication | Open Access

FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

DOI Full Paper Access

17

Citations

17

References

2024

Year

Laura K. Ferris, Jerry Bagel, Yu-Huei Huang, Andrew Pink, Stephen K. Tyring, Georgios Kokolakis, Amy M. DeLozier, Shu Li, Yaung-Kaung Shen, Charles Iaconangelo,

Journal of the American Academy of Dermatology

Abstract

Rates of skin clearance with JNJ-77242113 were durable to 1 year and no safety signals were identified.

References

	Year	Citations

Page 1